Literature DB >> 3355277

Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus.

A D Hilgenberg1, R W Carey, E W Wilkins, N C Choi, D J Mathisen, H C Grillo.   

Abstract

In an attempt to improve on the long-term survival rate of patients with esophageal squamous cell carcinoma, we designed a study in which treatment included preoperative chemotherapy with fluorouracil and cisplatin, surgical resection, and selective postoperative chemotherapy or radiation therapy. Between 1981 and 1986, 35 patients with potentially resectable lesions were entered into the study. After chemotherapy, 13 of 35 patients (37%) had a complete clinical response, 7 (20%) had a partial response, and 15 (43%) had no response. One patient sustained a serious toxic reaction (renal failure). Twenty-seven patients underwent surgical resection, with 1 hospital death (3.7%). Selective postoperative radiotherapy or chemotherapy was administered to 69%. The actuarial survival of all resected patients at 42 months was 54% (standard error, 10%). Multivariate analysis showed significant factors associated with 3-year survival were: (1) complete clinical response to chemotherapy; (2) absence of wall penetration in the specimen; and (3) microscopic or no disease in the specimen. We conclude that this multimodality treatment method improves the intermediate-term survival of patients with squamous cell carcinoma of the esophagus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355277     DOI: 10.1016/s0003-4975(98)90004-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  22 in total

1.  Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect.

Authors:  Y Hosoya; H Shibusawa; H Nagai; I Ueno; K Sakuma; T Nagashima; N Kobayashi; K Kanazawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Usefulness of preoperative low dose cisplatin treatment for advanced esophageal cancer.

Authors:  M Imamura; Y Shimada; Y Kanda; M Fukumoto; K Yanagibashi; T Miyahara; T Tobe
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

3.  Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.

Authors:  H Sekiguchi; S Akiyama; M Fujiwara; H Nakamura; K Kondo; Y Kasai; K Ito; J Sakamoto; H Takagi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

4.  The results of esophagogastrectomy without thoracotomy for adenocarcinoma of the esophagogastric junction.

Authors:  R J Finley; R I Inculet
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

5.  Operable esophageal cancer: current results from the West.

Authors:  A Watson
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

Review 6.  Multimodal treatment for squamous cell esophageal cancer.

Authors:  U Fink; H J Stein; H Wilke; J D Roder; J R Siewert
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 7.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

8.  A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.

Authors:  F Mühr-Wilkenshoff; W Hinkelbein; I Ohnesorge; K J Wolf; E-O Riecken; M Zeitz; H Scherübl
Journal:  Int J Colorectal Dis       Date:  2003-02-01       Impact factor: 2.571

9.  Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer.

Authors:  Tadasuke Hashiguchi; Motomi Nasu; Takashi Hashimoto; Tetsuji Kuniyasu; Hirohumi Inoue; Noritaka Sakai; Kazutomo Ouchi; Takayuki Amano; Fuyumi Isayama; Natsumi Tomita; Yoshimi Iwanuma; Masahiko Tsurumaru; Yoshiaki Kajiyama
Journal:  Mol Clin Oncol       Date:  2014-06-19

10.  Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy.

Authors:  S J Darnton; S M Allen; C W Edwards; H R Matthews
Journal:  J Clin Pathol       Date:  1993-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.